**Core Concept**
Pneumocystis jirovecii pneumonia (PCP) is a type of opportunistic infection that primarily affects individuals with weakened immune systems, particularly those with HIV/AIDS. Prophylaxis is essential to prevent PCP in high-risk populations.

**Why the Correct Answer is Right**
Prophylaxis for PCP is indicated in individuals with a CD4 count < 200 cells/μL, a history of PCP, or those receiving immunosuppressive therapy. This is because a compromised immune system makes them susceptible to PCP. Trimethoprim-sulfamethoxazole (TMP-SMX) is the recommended first-line prophylactic agent, as it targets the folate synthesis pathway in Pneumocystis jirovecii, leading to inhibition of its growth. **Why Each Wrong Option is Incorrect** **Option A:** This option is incorrect as it does not specify a condition that would necessitate PCP prophylaxis. **Option B:** This option is incorrect as it does not accurately represent a condition that warrants prophylaxis. **Option C:** This option is incorrect as it does not correctly identify a condition that would require PCP prophylaxis. **Clinical Pearl / High-Yield Fact** A CD4 count < 200 cells/μL is a critical threshold for initiating PCP prophylaxis in HIV-positive individuals. This is a key point to remember when assessing patients with HIV/AIDS. **Correct Answer: D. Individuals with a CD4 count < 200 cells/μL, a history of PCP, or those receiving immunosuppressive therapy.**